Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF).
Adrenergic beta-Antagonists
/ therapeutic use
Angiotensin Receptor Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Coronary Artery Bypass
/ methods
Coronary Artery Disease
/ complications
Cost-Benefit Analysis
Diuretics
/ therapeutic use
Follow-Up Studies
Heart Failure
/ etiology
Humans
Myocardial Ischemia
/ complications
Prognosis
Prospective Studies
Randomized Controlled Trials as Topic
Stroke Volume
Treatment Outcome
Ventricular Dysfunction, Left
/ complications
Ischemic cardiomyopathy, Ventricular dysfunction, Coronary artery disease, CABG, Randomized controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
16 Apr 2020
16 Apr 2020
Historique:
received:
21
11
2019
accepted:
20
03
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Ischemic cardiomyopathy and severe left ventricular dysfunction are well established to represent the main determinants of poor survival and premature death compared with preserved ventricular function. However, the role of myocardial revascularization as a therapeutic alternative is not known to improve the long-term prognosis in this group of patients. This study will investigate whether myocardial revascularization contributes to a better prognosis for patients compared with those treated with drugs alone and followed over the long term. The study will include 600 patients with coronary artery disease associated with ischemic cardiomyopathy. The surgical or drug therapy option will be randomized, and the events considered for analysis will be all-cause mortality, nonfatal infarction, unstable angina requiring additional revascularization, and stroke. The events will be analyzed according to the intent-to-treat principle. Patients with multivessel coronary disease and left ventricular ejection fraction measurements of less than 35% will be included. In addition, myocardial ischemia will be documented by myocardial scintigraphy. Markers of myocardial necrosis will be checked at admission and after the procedure. The role of myocardial revascularization (CABG) in the treatment of patients with coronary artery disease and heart failure is not clearly established. The surgical option of revascularizing the myocardium is a procedure designed to reduce the load of myocardial hibernation in patients with heart failure caused by coronary artery disease. On the other hand, the assessment of myocardial viability is frequently used to identify patients with left ventricular ischemic dysfunction in which CABG may add survival benefit. However, the effectiveness of this option is uncertain. The great difficulty in establishing the efficacy of surgical intervention is based on the understanding of viability without ischemia. Thus, this study will include only patients with viable and truly ischemic myocardium to correct this anomaly. Evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy submitted to medical or surgical treatment: MASS-VI (HF), ISRCTN77449548, Oct 10th, 2019 (retrospectively registered).
Sections du résumé
BACKGROUND
BACKGROUND
Ischemic cardiomyopathy and severe left ventricular dysfunction are well established to represent the main determinants of poor survival and premature death compared with preserved ventricular function. However, the role of myocardial revascularization as a therapeutic alternative is not known to improve the long-term prognosis in this group of patients. This study will investigate whether myocardial revascularization contributes to a better prognosis for patients compared with those treated with drugs alone and followed over the long term.
METHODS
METHODS
The study will include 600 patients with coronary artery disease associated with ischemic cardiomyopathy. The surgical or drug therapy option will be randomized, and the events considered for analysis will be all-cause mortality, nonfatal infarction, unstable angina requiring additional revascularization, and stroke. The events will be analyzed according to the intent-to-treat principle. Patients with multivessel coronary disease and left ventricular ejection fraction measurements of less than 35% will be included. In addition, myocardial ischemia will be documented by myocardial scintigraphy. Markers of myocardial necrosis will be checked at admission and after the procedure.
DISCUSSION
CONCLUSIONS
The role of myocardial revascularization (CABG) in the treatment of patients with coronary artery disease and heart failure is not clearly established. The surgical option of revascularizing the myocardium is a procedure designed to reduce the load of myocardial hibernation in patients with heart failure caused by coronary artery disease. On the other hand, the assessment of myocardial viability is frequently used to identify patients with left ventricular ischemic dysfunction in which CABG may add survival benefit. However, the effectiveness of this option is uncertain. The great difficulty in establishing the efficacy of surgical intervention is based on the understanding of viability without ischemia. Thus, this study will include only patients with viable and truly ischemic myocardium to correct this anomaly.
TRIAL REGISTRATION
BACKGROUND
Evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy submitted to medical or surgical treatment: MASS-VI (HF), ISRCTN77449548, Oct 10th, 2019 (retrospectively registered).
Identifiants
pubmed: 32299458
doi: 10.1186/s13063-020-04270-w
pii: 10.1186/s13063-020-04270-w
pmc: PMC7164251
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Diuretics
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337Références
Killip T, Passamani E, Davis K. Coronary Artery Surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68:939–50.
doi: 10.1161/01.CIR.68.5.939
Murphy M, Hultgren H, Detre K, Thomsen J, Takaro T. Participants of the Veterans Administration Cooperative Study. Treatment of chronic stable angina: a preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med. 1977;297:621.
doi: 10.1056/NEJM197709222971201
European Coronary Surgery Study Group. Long-term results of prospective randomized study of coronary artery bypass surgery on stable angina pectoris. Lancet. 1982;2:1173.
Detre K, Peduzzi P, Murphy M, Hultgren H, Thomsen J, Oberman A, et al. Effect of bypass surgery on survival in patients in low- and high-risk subgroups delineated by use of simple clinical variables. Circulation. 1981;63:1329–38.
doi: 10.1161/01.CIR.63.6.1329
Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman R, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645–58.
doi: 10.1161/01.CIR.90.6.2645
Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–25 [Erratum, N Engl J Med. 1997;336:147].
doi: 10.1056/NEJM199607253350401
BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.
doi: 10.1056/NEJMoa0805796
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84.
doi: 10.1056/NEJMoa1211585
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.
doi: 10.1056/NEJMoa1100356
Ware JE, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
doi: 10.1097/00005650-199206000-00002
Girardi PB, Hueb W, Nogueira CR, Takiuti ME, Nakano T, Garzillo CL, Paulitsch Fda S, Góis AF, Lopes NH, Stolf NA. Comparative costs between myocardial revascularization with or without extracorporeal circulation. Arq Bras Cardiol. 2008;91(6):340–6.
doi: 10.1590/S0066-782X2008001800003